Good Therapeutics
Founded Year
2016Stage
Acquired | AcquiredTotal Raised
$30.19MValuation
$0000About Good Therapeutics
Good Therapeutics is a biopharmaceutical company focused on the generation of a new class of drugs that offer potent activity only where it is needed. The company's therapeutics is combined with a sensor component, that targets any molecule that an antibody can bind, including native proteins, modified proteins, and metabolites, enabling healthcare providers to build therapies that maximize the benefit for patients without sacrificing safety. The company was founded in 2016 and is based in Seattle, Washington. In September 2022, Good Therapeutics was acquired by Roche Holding.
Missing: Good Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Good Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Good Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Good Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Good Therapeutics Patents
Good Therapeutics has filed 1 patent.
The 3 most popular patent topics include:
- Cell biology
- Clusters of differentiation
- Molecular biology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/18/2021 | Proteins, Protein domains, Clusters of differentiation, Molecular biology, Cell biology | Application |
Application Date | 10/18/2021 |
|---|---|
Grant Date | |
Title | |
Related Topics | Proteins, Protein domains, Clusters of differentiation, Molecular biology, Cell biology |
Status | Application |
Latest Good Therapeutics News
Nov 16, 2022
16-11-2022 Bonum Therapeutics, a biopharma using allosteric regulation to create conditionally active and less toxic medicines, has announced a $93 million Series A financing. The Seattle, USA-based firm is a spinout of Good Therapeutics, which Swiss pharma giant Roche (ROG: SIX) acquired in August 2022 for $250 million upfront plus potential milestone payments. Investors that financed Good Therapeutics, including Rivervest Venture Partners, Roche Venture Fund,… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login . If your trial has come to an end, you can subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK
Good Therapeutics Frequently Asked Questions (FAQ)
When was Good Therapeutics founded?
Good Therapeutics was founded in 2016.
Where is Good Therapeutics's headquarters?
Good Therapeutics's headquarters is located at 1616 Eastlake Avenue East, Seattle.
What is Good Therapeutics's latest funding round?
Good Therapeutics's latest funding round is Acquired.
How much did Good Therapeutics raise?
Good Therapeutics raised a total of $30.19M.
Who are the investors of Good Therapeutics?
Investors of Good Therapeutics include Roche Holding, RiverVest Venture Partners, Roche Venture Fund, 3x5 Partners, Digitalis Ventures and 3 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.